DK1789402T3 - 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes - Google Patents
2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetesInfo
- Publication number
- DK1789402T3 DK1789402T3 DK05772372.8T DK05772372T DK1789402T3 DK 1789402 T3 DK1789402 T3 DK 1789402T3 DK 05772372 T DK05772372 T DK 05772372T DK 1789402 T3 DK1789402 T3 DK 1789402T3
- Authority
- DK
- Denmark
- Prior art keywords
- ylmethoxymethyl
- cyclohexylmethoxy
- oxazol
- hyperlipidemia
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004039533A DE102004039533B4 (de) | 2004-08-14 | 2004-08-14 | Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| PCT/EP2005/008284 WO2006018118A1 (de) | 2004-08-14 | 2005-07-30 | 2-{-3-`2-(phenyl)-oxazol-4-ylmethoxymethyl!-cyclohexylmethoxy}-propionsäure derivate als ppar-liganden (peroxisomen-proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidämie und diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1789402T3 true DK1789402T3 (da) | 2010-03-22 |
Family
ID=35376939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05772372.8T DK1789402T3 (da) | 2004-08-14 | 2005-07-30 | 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7538131B2 (da) |
| EP (1) | EP1789402B1 (da) |
| JP (1) | JP2008509894A (da) |
| KR (1) | KR20070046116A (da) |
| CN (1) | CN101014579A (da) |
| AR (1) | AR050121A1 (da) |
| AT (1) | ATE449086T1 (da) |
| AU (1) | AU2005274495A1 (da) |
| BR (1) | BRPI0514360A (da) |
| CA (1) | CA2576584A1 (da) |
| DE (2) | DE102004039533B4 (da) |
| DK (1) | DK1789402T3 (da) |
| ES (1) | ES2335513T3 (da) |
| IL (1) | IL181011A0 (da) |
| MX (1) | MX2007000846A (da) |
| PA (1) | PA8641601A1 (da) |
| PE (1) | PE20060643A1 (da) |
| PT (1) | PT1789402E (da) |
| TW (1) | TW200621733A (da) |
| UY (1) | UY29064A1 (da) |
| WO (1) | WO2006018118A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100915108B1 (ko) * | 2001-08-31 | 2009-09-03 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｐｐａｒ-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물 |
| DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
-
2004
- 2004-08-14 DE DE102004039533A patent/DE102004039533B4/de not_active Expired - Fee Related
-
2005
- 2005-07-30 CN CNA2005800271483A patent/CN101014579A/zh active Pending
- 2005-07-30 CA CA002576584A patent/CA2576584A1/en not_active Abandoned
- 2005-07-30 WO PCT/EP2005/008284 patent/WO2006018118A1/de active Application Filing
- 2005-07-30 DE DE502005008552T patent/DE502005008552D1/de active Active
- 2005-07-30 ES ES05772372T patent/ES2335513T3/es active Active
- 2005-07-30 PT PT05772372T patent/PT1789402E/pt unknown
- 2005-07-30 BR BRPI0514360-8A patent/BRPI0514360A/pt not_active IP Right Cessation
- 2005-07-30 DK DK05772372.8T patent/DK1789402T3/da active
- 2005-07-30 JP JP2007525218A patent/JP2008509894A/ja not_active Abandoned
- 2005-07-30 EP EP05772372A patent/EP1789402B1/de not_active Not-in-force
- 2005-07-30 KR KR1020077003579A patent/KR20070046116A/ko not_active Application Discontinuation
- 2005-07-30 AT AT05772372T patent/ATE449086T1/de not_active IP Right Cessation
- 2005-07-30 AU AU2005274495A patent/AU2005274495A1/en not_active Abandoned
- 2005-07-30 MX MX2007000846A patent/MX2007000846A/es active IP Right Grant
- 2005-08-10 PE PE2005000925A patent/PE20060643A1/es not_active Application Discontinuation
- 2005-08-11 AR ARP050103350A patent/AR050121A1/es not_active Application Discontinuation
- 2005-08-11 TW TW094127241A patent/TW200621733A/zh unknown
- 2005-08-12 UY UY29064A patent/UY29064A1/es unknown
- 2005-08-12 PA PA20058641601A patent/PA8641601A1/es unknown
-
2007
- 2007-01-28 IL IL181011A patent/IL181011A0/en unknown
- 2007-02-02 US US11/670,594 patent/US7538131B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101014579A (zh) | 2007-08-08 |
| BRPI0514360A (pt) | 2008-07-15 |
| US20070197612A1 (en) | 2007-08-23 |
| EP1789402B1 (de) | 2009-11-18 |
| ATE449086T1 (de) | 2009-12-15 |
| WO2006018118A1 (de) | 2006-02-23 |
| PE20060643A1 (es) | 2006-07-26 |
| WO2006018118A8 (de) | 2006-05-18 |
| US7538131B2 (en) | 2009-05-26 |
| UY29064A1 (es) | 2006-02-24 |
| AR050121A1 (es) | 2006-09-27 |
| AU2005274495A1 (en) | 2006-02-23 |
| IL181011A0 (en) | 2007-07-04 |
| DE502005008552D1 (de) | 2009-12-31 |
| TW200621733A (en) | 2006-07-01 |
| JP2008509894A (ja) | 2008-04-03 |
| MX2007000846A (es) | 2007-04-17 |
| CA2576584A1 (en) | 2006-02-23 |
| EP1789402A1 (de) | 2007-05-30 |
| PT1789402E (pt) | 2010-02-01 |
| KR20070046116A (ko) | 2007-05-02 |
| ES2335513T3 (es) | 2010-03-29 |
| DE102004039533A1 (de) | 2006-03-02 |
| PA8641601A1 (es) | 2006-03-24 |
| DE102004039533B4 (de) | 2006-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1789403T3 (da) | N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| NO20054396D0 (no) | 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose | |
| DK1756084T3 (da) | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed | |
| DK1651622T3 (da) | Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser | |
| DK1817282T3 (da) | Til behandling af respiratoriske sygdomme egnede phenoxy derivater | |
| DK2173730T3 (da) | Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter | |
| DK2177224T3 (da) | Forbindelse til forebyggelse og behandling af lidelser, som involverer modulation af RyR-receptorerne | |
| DK1471057T3 (da) | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 | |
| DK1942898T3 (da) | Dipeptidylpeptidase-inhibitorer til behandling af diabetes | |
| ATE550329T1 (de) | Heterobicyclische sulfonamidderivate zur behandlung von diabetes | |
| DK1701944T3 (da) | 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme | |
| NO20055370D0 (no) | Alfa-substituert karboksylsyre som PPAR modulatorer | |
| DK1611108T3 (da) | Fremgangsmåde til fremstilling af telmisartan | |
| DK1734959T3 (da) | Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter | |
| DK1801108T3 (da) | Morpholinforbindelser til behandling af inflammationer. | |
| DK1871380T3 (da) | Kombineret anvendelse af prostaglandinforbindelse og protonpumpeinhibitor til behandlingen af gastrointestinale lidelser | |
| DK1539746T3 (da) | N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes | |
| ATE362367T1 (de) | Phenoxyessigsäure-derivate als peroxisom- proliferator-aktivierte rezeptor (ppar) dual- agonisten | |
| ATE525355T1 (de) | 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1 | |
| SG138604A1 (en) | Modulation of peroxisome proliferator-activated receptors | |
| DK1789402T3 (da) | 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy)-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| DK1778655T3 (da) | 2-{-3-'2-(phenyl)-oxazol-4-ylmethoxy!-cyclohexylmethoxy}-propionsyrederivater som PPAR-ligander (peroxisomen-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes | |
| DK2010538T3 (da) | Fremgangsmåde til fremstilling af [(1R), 2S]-2-aminopropionsyre 2-[4-(4-fluor-2-methyl-1H-indol-5-yloxy)-5-methylpyrrol]2,1-f-[1,2,4-triazin-6-yloxy]-1-methylethylester | |
| DK1517883T3 (da) | Ortho-substituerede benzoesyrederivater til behandling af insulinresistens | |
| DK1993524T3 (da) | Anvendelse af bupropionmetabolitter til behandling af inflammatoriske lidelser |